CD86 and myalgic encephalomeyelitis/chronic fatigue syndrome: Whereas 96-99% of all DICAM+ CFS mononuclear cells from both symptomatic controls, untreated and natalizumab-treated patients expressed CD86, significant less DICAM+ CFS mononuclear cells from untreated patients (35%) compared to both symptomatic controls (47%) and natalizumab-treated patients (46%) expressed CD206.